15.05.2019 • NewsBiotechnologyPharmaceuticalsNeurology

Bionure Appoints Lucia Septien as Chief Medical Officer

Bionure has appointed Lucia Septien as chief medical officer. Source: Bionure
Bionure has appointed Lucia Septien as chief medical officer. Source: Bionure

Bionure, a Barcelona, Spain-based clinical stage R&D company specialized in the treatment of neurodegenerative diseases, has appointed Lucia Septien as chief medical officer (CMO).

Septien joins Bionure from DBV Technologies where she also held the CMO position. Prior to that, she worked as a clinical doctor in neurology and psychiatry and then held diverse roles at major pharmaceutical companies, including Pfizer, Wyeth, GSK, Servier and Ipsen.

"We warmly welcome Lucia to Bionure. With her sensitivity for patients, her solid experience in CNS drug development and her leadership skills, she will strengthen our team," said Laurent Nguyen, CEO of Bionure. “We are convinced of her ability to successfully implement our neuroprotection projects.”

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.